Clinical Trials Logo
  1. Home
  2. Antibiotic Resistant Infection
  3. NCT03866291
  4. Details
NCT03866291 Clinical Trial

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

Antibiotic Resistant Infection Clinical Trial

Official title:
ESBL-producing Enterobacteriaceae in Patients With Traveller's Diarrhoea- a Prospective Cohort Study.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03866291
Other study ID # 2017-0123
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2017
Est. completion date June 20, 2019

Study information
Verified date July 2019
Source Lund University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas.

This study investigates to what extent travellers returning to Sweden with traveller's diarrhoea carry ESBL in their stool. The isolates are examined further according to species, phenotype, antibiogram and whole genome sequencing.

Description:

Samples sent to the department of clinical microbiology in Lund, Sweden for culture of salmonella, shigella, yersinia or campylobacter are also cultured selectively for ESBL.

All patients are contacted by mail with the results. ESBL-positive patients are invited to submit further faecal cultures and blood samples during one year follow up time, to investigate how long the patient is colonized with ESBL.

Recruitment information / eligibility
Status Completed
Enrollment 305
Est. completion date June 20, 2019
Est. primary completion date June 20, 2019
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Travellers diarrhoea

- foreign traveller

Exclusion Criteria:

- foreign traveller but no symptoms

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• No intervention, observational
See above

Locations
Country Name City State
Sweden Oskar Ljungquist Helsingborg Skåne

Sponsors (1)
Lead Sponsor Collaborator
Lund University

Country where clinical trial is conducted

Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Proportion ESBL-colonized after one year. Defined as a Positive ESBL-culture obtained 12 months after travel 1 year
See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05502380 - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Phase 3
Withdrawn NCT04462133 - Optimal Tailored Treatment for H. Pylori Infection N/A
Completed NCT03535324 - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT) N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Not yet recruiting NCT06028217 - Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
Completed NCT05391035 - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting NCT05224401 - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs Phase 3
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Terminated NCT03535272 - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Phase 3
Recruiting NCT05902299 - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting NCT05293483 - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting NCT05561504 - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting NCT03606031 - Digestive Microbiota Transplant
Completed NCT01573195 - Merck IISP Stewardship Grant for Antibiotic Best Practices Phase 4
Not yet recruiting NCT03857295 - Infections Following NeuroSurgery (INS)